<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169021">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896532</url>
  </required_header>
  <id_info>
    <org_study_id>20060326</org_study_id>
    <nct_id>NCT00896532</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density</brief_title>
  <official_title>A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 clinical trial will study the safety and efficacy of AMG 785, an
      investigational bone building agent, in the treatment of postmenopausal women with low bone
      mineral density. Different doses and dosing frequencies of AMG 785 will be compared to
      placebo in a double-blind fashion. In addition, AMG 785 will be compared to open label
      alendronate and open label teriparatide.

      The clinical hypothesis is that AMG 785 compared with placebo will cause a greater percent
      change from baseline in lumbar spine bone mineral density.

      At the end of the initial 24 months treatment phase, eligible subjects will enter a 12
      months extension phase. Subjects will be randomized 1:1 within their original treatment
      group to receive either denosumab or placebo every 6 months Subjects not participating in
      the 12 months extension phase will be followed for an additional three months to Month 27.

      At the end of the 12 month extension phase, eligible subjects will enter a 12 month
      retreatment phase. All subjects participating in the re-treatment phase will receive 210 mg
      of AMG 785 QM for 12 months. Subjects not participating in the 12 month re-treatment phase
      will complete the study at Month 36. At the end of the 12 month AMG 785 retreatment phase,
      subjects will enter a 24 month follow-on phase. Based on the outcome of the eligibility
      assessment, subjects will either receive one dose of 5 mg ZOL intravenously or no
      intervention. Subjects not participating in the 24 month follow-on phase will be followed
      for an additional 3 month observational period to month 51.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline at month 12 in bone mineral density at the lumbar spine for the individual AMG 785 groups and pooled placebo arms.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at month 12 in bone mineral density at the total hip, femoral neck and distal radius for the individual AMG 785 groups and pooled placebo arms.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at month 1, 3, 6, 9 and 12 in bone turnover markers for the individual AMG 785 groups and pooled placebo arms.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature, frequency, severity of adverse events &amp; their relationship to treatment; Changes from baseline in vital signs, laboratory assessments, ECG parameters; Bone histologic &amp; histomorphometric pameters; Formation of anti-AMG 785 antibodies</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at month 24 in bone mineral density for the individual AMG 785 groups and pooled placebo arms.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Quantitative Computed Tomography (QCT) BMD &amp; variables for AMG 785 and teriparatide groups during the first year</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline at month 6 in bone mineral density at the lumbar spine, total hip and femoral neck for the individual AMG 785 groups and pooled placebo arms.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature, frequency and severity of adverse events and their relationship to treatment; Changes</measure>
    <time_frame>24-36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline and month 48 to months 54, 60, 66, and 72 in BMD at the lumbar spine, total hip, and femoral neck.</measure>
    <time_frame>72 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline and month 48 to months 51, 54, 60, 66, and 72 in BTMs.</measure>
    <time_frame>72 months</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">419</enrollment>
  <condition>Low Bone Mineral Density</condition>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>AMG 785 70 mg or placebo SC QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 785 70mg or 140mg or 210mg SC or placebo SC every month (QM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open label TPTD 20 μg SC every day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Teriparatide 20ug SC every day (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 785 140 mg or placebo SC QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 785 140mg or 210mg SC or placebo SC every three months (Q3M)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open label ALN 70 mg PO every week</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate (Fosamax) 70mg PO every week (QW)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab 60 mg SC or placebo SC (Q6M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60 mg SC or placebo SC administration every 6 months (Q6M)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 785 210 mg or placebo SC Q3M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 785 210 mg or placebo SC every month (QM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronic acid 5 mg IV or no interv</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic acid 5 mg IV or no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator Alendronate</intervention_name>
    <description>70mg PO every week (QW)</description>
    <arm_group_label>Open label ALN 70 mg PO every week</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC Q3M</description>
    <arm_group_label>AMG 785 140 mg or placebo SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>140mg SC QM</description>
    <arm_group_label>AMG 785 70 mg or placebo SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>140mg SC Q3M</description>
    <arm_group_label>AMG 785 140 mg or placebo SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>210mg SC Q3M</description>
    <arm_group_label>AMG 785 140 mg or placebo SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC QM</description>
    <arm_group_label>AMG 785 70 mg or placebo SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator teriparatide</intervention_name>
    <description>20µg SC every day (QD)</description>
    <arm_group_label>Open label TPTD 20 μg SC every day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>210mg SC QM</description>
    <arm_group_label>AMG 785 70 mg or placebo SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>70mg SC QM</description>
    <arm_group_label>AMG 785 70 mg or placebo SC QM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>60 mg SC Q6M</description>
    <arm_group_label>Denosumab 60 mg SC or placebo SC (Q6M)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 785</intervention_name>
    <description>210mg SC QM</description>
    <arm_group_label>AMG 785 210 mg or placebo SC Q3M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>5 mg IV</description>
    <arm_group_label>Zoledronic acid 5 mg IV or no interv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Denosumab 60 mg SC or placebo SC (Q6M)</arm_group_label>
    <other_name>Placebo SC administration every 6 months (Q6M)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC Q3M</description>
    <arm_group_label>AMG 785 210 mg or placebo SC Q3M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, postmenopausal women, aged ≥ 55 to ≤ 85

          -  Low BMD measured by Dual energy X-ray Absorptiometry (DXA) and assessed by the
             central imaging vendor (equivalent to T-scores between -2.0 and -3.5)

        Exclusion Criteria:

          -  History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or
             pelvis after age 50

          -  Untreated hyper- or hypothyroidism

          -  Current hyper- or hypoparathyroidism, hypo- or hypercalcemia

          -  Elevated transaminases

          -  Significantly impaired renal function

          -  Positive for: HIV, Hep-C or Hep-B surface antigen

          -  Malignancy

          -  History of solid organ or bone marrow transplants

          -  Use of agents affecting bone metabolism

          -  Contraindicated or intolerant of alendronate therapy

          -  Contraindicated or intolerant of teriparatide therapy

        Inclusion Criteria for the 12 month extension phase (Month 24 to 36):

          -  Normocalcemia at or after the Month 21 visit but before the Month 24 study visit
             Exclusion Criteria for the 12 month extension phase (Month 24 to 36)

          -  Incidence of a clinical vertebral fracture or fragility fracture of the wrist,
             humerus, hip or pelvis during the initial 24 month treatment phase of the study

          -  A BMD loss of ≥ 7.0% from baseline at any time up to the Month 18 visit of the
             initial 24-month treatment phase

          -  Malignancy

          -  History of osteonecrosis of the jaw

          -  Use of proscribed medication during the initial 24 month treatment phase

          -  Contraindicated or intolerant of denosumab therapy

        Inclusion Criteria for the 12 month re-treatment phase (Month 36 to 48) albumin adjusted
        serum calcium of the most recent blood draw at or after the Month 30 visit but before the
        Month 36 study visit. Calcium repletion is permitted and central laboratory analysis of
        albumin adjusted serum calcium may be repeated before the Month 36 study visit

          -  Participation in Group A or B during initial 24 month treatment phase

          -  Subject has reached M36 of the study

          -  Appropriate written informed consent must be obtained

        Exclusion Criteria for the 12 month re-treatment phase (Month 36 to 48)

          -  New malignancy

          -  Use of proscribed medication during the 12 month extension phase

        Inclusion Criteria for the 24 month follow-on phase (Month 48 to 72) General inclusion
        criteria for participation

          -  Subject has reached month 48 of the study

          -  Appropriate written ICF must be obtained Inclusion criteria for assignment to the no
             intervention group

          -  During the 24 month AMG 785 treatment phase, subject was assigned to any AMG 785
             treatment group

          -  During the 12 month denosumab extension phase, subject was assigned to the denosumab
             treatment group Exclusion for the 24 month follow-on phase (Month 48 to 72)

          -  New malignancy

          -  Use of proscribed meds during the 12 month re-treatment phase

          -  Partial ICF withdrawal and discontinuation of IP at any time up to month 48 visit

          -  Incidence of a clinical vertebral fracture or fragility fracture of the wrist,
             humerus, hip or pelvis during the initial 24 month treatment phase of the study

          -  BMD T-score of ≤ -2.5 at the lumbar spine, total hip, or femoral neck based on local
             read of the DXA scans at month 48

          -  Intolerance to Zoledronic acid
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>10.1002/jbmr.2932</citation>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>May 7, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>April 16, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
